Maker of Wegovy and Ozempic has 45,000 patients in clinical trials as it seeks to stave off threats from Eli Lilly and Roche
Weight loss group announces overhaul to stay relevant amid boom in demand for new medications
For years, the process for developing and testing new drugs has focused disproportionately on male bodies — to the detriment of female patients
UK pharmaceutical group forecasts 7-9% revenue growth this year on strong performance from cancer and HIV drugs
Nice blames cost for not recommending Enhertu, which has helped patients in clinical trials live longer
Swiss drugmaker unveils promising data for obesity drug
Extreme shortages of actinium are holding up the promising field of radiopharmaceuticals
Eisai and Biogen face uphill battle to win EU approval for Leqembi after committee’s ruling
GSK’s Shingrix is latest drug to show potential for targeting previously untreatable brain disorders
Pascal Soriot criticises decision to block breast cancer drug in England as FTSE 100 group raises profit outlook
Long waiting list for drug because of shortage of specialist services could hit patients unable to pay privately
Pharma groups could see almost threefold drop in demand due to US health official decision, says Airfinity
Sergey Brin’s non-profit funds research into using hallucinogen for mental health treatment
The next generation of drugs vying for a slice of the potential $150bn obesity market
Shares are down 70% for the world’s largest maker of insulin pen needles and syringes since it was spun off
After a peak pandemic surge, interest in the sector has dried up
Swiss drugmaker says it will only sell medication privately if health systems cannot pay
There is concern that medications used widely for weight loss have not been tested for use by pregnant women
Federal authorities are proposing to reclassify marijuana as a less dangerous drug
Use of Car-T for lupus could drive surge in demand for a treatment that was first approved for blood cancers
Pharma group seeks to catch up with rivals Eli Lilly and Novo Nordisk in sector projected to be worth $130bn a year
US-listed pharmacy group’s problems have been exacerbated by its struggle to move into healthcare
Incubator Flagship Pioneering plans to finance and launch array of companies using AI for pharmaceutical development
Spanish medicine maker was rocked earlier this year by allegations of fraud
Ageing is a long-term trend that investors can bank on
